Neurocrine Biosciences (NBIX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX):

• 2/11/2025 – Neurocrine Biosciences is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $138.00 price target on the stock.
• 2/10/2025 – Neurocrine Biosciences was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 2/10/2025 – Neurocrine Biosciences had its price target lowered by analysts at Guggenheim from $165.00 to $163.00. They now have a “buy” rating on the stock.
• 2/7/2025 – Neurocrine Biosciences had its price target lowered by analysts at Royal Bank of Canada from $154.00 to $148.00. They now have a “sector perform” rating on the stock.
• 2/7/2025 – Neurocrine Biosciences had its price target lowered by analysts at Wedbush from $157.00 to $147.00. They now have an “outperform” rating on the stock.
• 2/7/2025 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at William Blair.
• 2/7/2025 – Neurocrine Biosciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 2/7/2025 – Neurocrine Biosciences had its price target lowered by analysts at Canaccord Genuity Group Inc. from $172.00 to $163.00. They now have a “buy” rating on the stock.
• 2/7/2025 – Neurocrine Biosciences had its price target lowered by analysts at HC Wainwright from $190.00 to $185.00. They now have a “buy” rating on the stock.
• 2/7/2025 – Neurocrine Biosciences had its price target lowered by analysts at Bank of America Co. from $184.00 to $179.00. They now have a “buy” rating on the stock.
• 2/4/2025 – Neurocrine Biosciences had its price target raised by analysts at Morgan Stanley from $170.00 to $185.00. They now have an “overweight” rating on the stock.
• 1/30/2025 – Neurocrine Biosciences had its price target raised by analysts at UBS Group AG from $162.00 to $176.00. They now have a “buy” rating on the stock.
• 1/8/2025 – Neurocrine Biosciences had its price target raised by analysts at UBS Group AG from $142.00 to $162.00. They now have a “buy” rating on the stock.
• 12/23/2024 – Neurocrine Biosciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock.
• 12/23/2024 – Neurocrine Biosciences had its price target raised by analysts at Barclays PLC from $160.00 to $165.00. They now have an “overweight” rating on the stock.
• 12/20/2024 – Neurocrine Biosciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 12/16/2024 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at William Blair.
• 12/16/2024 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
• 12/16/2024 – Neurocrine Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.

Neurocrine Biosciences Trading Down 1.6 %

Shares of NASDAQ:NBIX opened at $116.85 on Wednesday. The firm has a 50 day simple moving average of $138.66 and a 200-day simple moving average of $131.23. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a market capitalization of $11.83 billion, a PE ratio of 35.52 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the transaction, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at $19,157,968. This represents a 32.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44. Following the transaction, the director now directly owns 517,030 shares in the company, valued at approximately $79,064,227.60. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 222,693 shares of company stock worth $32,718,279. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares in the last quarter. Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares in the last quarter. Lindbrook Capital LLC grew its position in Neurocrine Biosciences by 53.5% in the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock valued at $51,000 after acquiring an additional 130 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $61,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.